Turkmenistan

Medicines regulation in Turkmenistan is overseen by the Ministry of Health and Medical Industry. Applicants and MAHs must comply with national registration and post-marketing safety conditions and provide adverse-reaction or periodic safety information when required. The reviewed public official sources do not substantiate a universal EU-style local QPPV, PSMF, fixed MAH ICSR timetable, routine PSUR/PBRER schedule, blanket RMP obligation, formal signal-management process or dedicated GVP-inspection programme. The MAH should therefore maintain a documented global safety system and confirm every product- and route-specific reporting, risk-management, local-contact and inspection requirement with the competent authority before supply or authorisation. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.